Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys
Orphanet Journal of Rare Diseases · 2025
DOI: 10.1186/s13023-024-03416-2 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Orphanet Journal of Rare Diseases, 2025. Verfasst von Shoshana Revel-Vilk und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gaucher Unit and Pediatric Hematology/Oncology Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel. Hauptthemen laut MEDLINE: alpha-Galactosidase, Enzyme Replacement Therapy, Fabry Disease, Gaucher Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Switzerland, Takeda Development Center Americas, Inc., Lexington, MA, USA, Takeda Pharmaceuticals International AG.
Abstract (Originalsprache)
Background
Fabry disease and Gaucher disease are rare genetic disorders characterized by defective degradation of glycosphingolipids caused by enzymatic deficiencies in α–galactosidase A and β–glucocerebrosidase, respectively, and often require life-long treatment. Treatment options for these disorders include replacing the deficient enzymes via enzyme replacement therapy (ERT). Agalsidase alfa for Fabry disease and velaglucerase alfa for Gaucher disease are two ERT options with demonstrated efficacy, safety, and tolerability. ERT infusions administered by a health care provider (HCP) in the clinic/hospital, or at the patient’s home are considered HCP-supported infusions. Self-administration of ERT (by patient, partner, relative, or caregiver) is optional in patients who tolerate the HCP-supported infusions at home and have a suitable home environment. This analysis explored the safety profiles of self-administered agalsidase alfa (202 patients) and velaglucerase alfa (30 patients) versus HCP-supported infusions using data from the Fabry Outcome Survey (FOS) and Gaucher Outcome Survey (GOS) registries.
Results
The frequency of infusion-related reactions (IRRs) adverse events (AEs) recorded in the two registries was lower in patients self-administering (FOS: 4.5%, GOS: 0%) versus patients receiving HCP-supported infusions (FOS: 13.6%, GOS: 1.6%). In the FOS registry, AE rates per 100 patient-years (100PY) of follow-up were similar between the self-administration (7.99) and HCP-supported infusion (6.78) groups. In patients self-administering agalsidase alfa, cardiac disorders were the most frequently reported AEs (19 [9.4%] patients) and serious AEs (12 [5.9%]) and gastrointestinal disorders were the most frequently reported IRRs (3 [1.5%]). In the GOS registry, AE rates per 100PY were similar between self-administration (4.97) and HCP-supported infusion (4.67) groups. In patients self-administering velaglucerase alfa, skin and subcutaneous disorders (4 [13.3%]) and infections and infestations (2 [6.7%]) were the most reported AEs and serious AEs, respectively, and no IRRs were reported.
Conclusions
These findings suggest that self-administration of agalsidase alfa or velaglucerase alfa infusions are not associated with additional safety risks compared with HCP-supported infusions and are a suitable option for qualifying patients. Further research is warranted to support these findings and to explore further the long-term safety and efficacy of ERT self-administration. FOS trial registration: ClinicalTrials.gov, NCT03289065. Registered 01 April 2001, https://clinicaltrials.gov/study/NCT03289065 . GOS trial registration: ClinicalTrials.gov, NCT03291223. Registered 27 July 2010, https://classic.clinicaltrials.gov/ct2/show/NCT03291223 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gaucher Unit and Pediatric Hematology/Oncology Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
- Faculty of Medicine, Hebrew University, Jerusalem, Israel.
- Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London, London, UK.
- Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, MPS-Spain Medical Committee, Barcelona, Spain.
- Lysosomal Disorders Unit, Royal Free London NHS Foundation Trust, University College London, London, UK.
- The Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia.
ORCID-Profile: Uma Ramaswami, Majdolen Istaiti
Förderung
- Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Switzerland
- Takeda Development Center Americas, Inc., Lexington, MA, USA
- Takeda Pharmaceuticals International AG
- Takeda Development Center Americas, Inc.
Zitieren
APA
Revel-Vilk, S., Ramaswami, U., Pintos-Morell, G., Hughes, D., Nicholls, K., Reisin, R., Giugliani, R., Goker-Alpan, O., Istaiti, M., Gill, A., Scarpa, M., & Botha, J. (2025). Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-024-03416-2
Vancouver
Revel-Vilk S, Ramaswami U, Pintos-Morell G, Hughes D, Nicholls K, Reisin R, et al. Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys. Orphanet Journal of Rare Diseases. 2025. doi:10.1186/s13023-024-03416-2
BibTeX
@article{RevelVilk2025,
author = {Revel-Vilk, Shoshana and Ramaswami, Uma and Pintos-Morell, Guillem and Hughes, Derralynn and Nicholls, Kathy and Reisin, Ricardo and Giugliani, Roberto and Goker-Alpan, Ozlem and Istaiti, Majdolen and Gill, Aidan and Scarpa, Maurizio and Botha, Jaco},
title = {Safety analysis of self-administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys},
journal = {Orphanet Journal of Rare Diseases},
year = {2025},
doi = {10.1186/s13023-024-03416-2}
}
EUVIMED